SOHO State of the Art Update and Next Questions: IDH therapeutic targeting in AML Journal Article
| Authors: | DiNardo, C. D.; Stein, E. M. |
| Article Title: | SOHO State of the Art Update and Next Questions: IDH therapeutic targeting in AML |
| Abstract: | Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid differentiation and ultimately, to the development of AML. Inhibitors of mutant IDH1 and 2 have recently been approved by the US Food and Drug Administration and their use has led to clinical responses with prolonged duration of response. IDH inhibitors in combination with standard-of-care therapy and other small molecular inhibitors are now being used. © 2018 Elsevier Inc. |
| Keywords: | isocitrate dehydrogenase; acute myeloid leukemia; enasidenib; ivosidenib; beta-hydroxyglutarate |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 18 |
| Issue: | 12 |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-12-01 |
| Start Page: | 769 |
| End Page: | 772 |
| Language: | English |
| DOI: | 10.1016/j.clml.2018.10.007 |
| PUBMED: | 30416011 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 3 December 2018 -- Source: Scopus |
